Literature DB >> 23806495

Pushing the limits of radiation therapy for prostate cancer: where do we go next?

Mark V Mishra1, Timothy N Showalter.   

Abstract

There have been significant advancements in the quality and precision of radiation therapy (RT) for prostate cancer over the past two decades. The development and implementation of intensity-modulated radiation therapy has allowed for RT dose-escalation without parallel increases in treatment morbidity. Moreover, integration of androgen deprivation therapy with definitive RT has led to improvements in outcomes for certain subgroups of prostate cancer patients. In this review, we highlight several ongoing and developing technical advances that hold promise for further optimizing RT care, including proton beam therapy, inter- and intra-fractional image-guided dose-delivery, methods for improved target volume definition, and development of techniques for safely performing hypofractionation and stereotactic body radiotherapy. We also discuss the importance of investigating the potential benefit of integrating novel systemic therapies with prostate RT to further improve outcomes for patients with locally advanced prostate cancer.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23806495     DOI: 10.1053/j.seminoncol.2013.04.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

Review 1.  Concurrent chemoradiation for high-risk prostate cancer.

Authors:  Benjamin T Cooper; Nicholas J Sanfilippo
Journal:  World J Clin Oncol       Date:  2015-08-10

Review 2.  Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Authors:  Chang-Deng Hu; Richard Choo; Jiaoti Huang
Journal:  Front Oncol       Date:  2015-04-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.